Neurogene Inc.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare, devastating neurological diseases. The company utilizes its proprietary EXACT (Expression Attenuation Cell Therapy) technology platform to deliver transgene levels within a narrow, therapeutic range, avoiding the toxicities associated with conventional gene therapy over-expression. Their primary focus is on addressing unmet needs in disorders like Rett syndrome and CLN5 Batten disease. By combining internal manufacturing capabilities with advanced transgene regulation technology, Neurogene aims to provide potentially curative treatments for complex genetic conditions that have historically been difficult to target safely.